东瑞制药（控股）有限公司（股票代码：02348）于2026年2月3日披露2026年1月股份变动月报表，报告期截至2026年1月31日。公司注册股本维持在20,000,000,000股，面值为每股0.05港元，总额1,000,000,000港元，未见变动。
\n\n月报显示，公司已发行股份（不含库存股）由上月底的1,503,357,000股增至1,503,557,000股，增加200,000股。公司当月未呈列任何库藏股或回购注销安排，公共持股量亦符合相关规定。
\n\n根据公告，新增发行的200,000股源于2013购股权计划的行使，转换所得资金总额为180,000港元。截至1月底，期权相关股份数目及面值安排均已获得公司董事会正式授权。
\n\n公告同时确认，本月内所有发行、出售或转让股份均遵循香港联交所《上市规则》和相关法律规定。该月报由公司秘书彭洁玲签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.